1,030
Participants
Start Date
February 29, 2012
Primary Completion Date
May 31, 2017
Study Completion Date
April 30, 2024
Rituximab
• Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Lenalidomide
• Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
Rituximab - CHOP
six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles
Rituximab - CVP
eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,
Rituximab - Bendamustine
six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Concord Repatriation General Hospital, Concord
Nepean Hospital, Penrith
Wollongong Hospital, Wollongong
CHU Mont-Godinne, Yvoir
Tom Baker Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
Fraser Valley Cancer Centre, Surrey
BCCA - Vancouver Cancer Centre, Vancouver
Moncton Hospital, Moncton
Atlantic Health Sciences Corp - Saint John Regional Hospital, Halifax
Sunnybrook Health Sciences Centre, Toronto
UHN-Princess Margaret Hospital, Toronto
CHUM Hopital Notre-Dame, Montreal
McGill University Department of Oncology, Montreal
Hôpital de l'Enfant-Jesus, CHU de Quebec, Québec
Saskatoon Cancer Centre, Saskatoon
CHU Claude Huriez, Lille
Medizinische Klinik der Universität Tübingen, Tübingen
Uniklinik Köln, Cologne
LMU Munchën - Klinikum Grosshadern, München
Sant'Andrea Hospital, Rome
Policlinico Sant'Orsola-Malpighi, Bologna
Instituto Português Oncologia, Lisbon
Hospital Virgen del Rocio, Seville
Hospital Universitario Mutua de Terrassa, Terrassa
Hospital Universitario de Canarias, Santa Cruz de Tenerife
Hospital Son Llatzer, Palma
Hospital Clínico de Barcelona, Barcelona
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Universitario Vall d´Hebron, Barcelona
Institut Català d'Oncologia de Girona (ICO Girona), Girona
Hospital Ramon y Cajal, Madrid
Hospital Costa del Sol, Marbella
Hospital Universitario Salamanca, Salamanca
Hospital Clínico Universitario de Valencia, Valencia
Collaborators (1)
Celgene Corporation
INDUSTRY
The Lymphoma Academic Research Organisation
OTHER